Lynn J. Howie, MD, on ER+ Metastatic Breast Cancer: An FDA Treatment Analysis

2017 San Antonio Breast Cancer Symposium
Tweet this page

Lynn J. Howie, MD, of the U. S. Food & Drug Administration, discusses a pooled analysis of outcomes of older women with hormone receptor–positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine-based therapy (Abstract GS5-06).

Advertisement

Advertisement

Advertisement